-
Mashup Score: 7Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis - 19 hour(s) ago
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 10Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein - 2 day(s) ago
Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association’s (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in partnership with the Society for Urologic Oncology, these evidence-based guidelines highlight key changes from the 2016 and 2017 versions. The updates include the management of variant histologies,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7
Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance applications, emphasizing selective utilization and benefits post-BCG therapy. Dr. Williams references a study in Clinical Genitourinary Cancer, sharing insights from a study comparing blue and…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 21Genetic Overlap Discovered Between Cancerous and Non-Cancerous Bladder Tissue in Small Study - Roger Li - 5 day(s) ago
Sam Chang and Roger Li delve into a study examining genetic profiles in non-muscle invasive bladder cancer and adjacent benign bladder tissue. Conducted on a cohort of nine patients, the study leveraged whole exome sequencing to explore mutations in both cancerous and non-cancerous tissue samples, uncovering a significant mutation overlap yet a lower mutation count in benign tissues. This…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 22Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian - 11 day(s) ago
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis - Beyond the Abstract - 16 day(s) ago
non-muscle invasive bladder cancer (NMIBC), transurethral resection of the bladder tumor (TURBT), Tumor T stage, cancer-specific survival (CSS) in patients with non-muscle invasive bladder cancer (NMIBC).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3
Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Navigating NMIBC Risk Stratification and Treatment - Neal Shore - 19 day(s) ago
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Navigating #NMIBC risk stratification and treatment. Neal Shore @CURCMB joins @UroDocAsh @MDAndersonNews to discuss the crucial role of the @AmerUrological guidelines, developed with significant contributions from Dr. Kamat and other leaders in the field > https://t.co/dB8GTF878o https://t.co/ZTPe2rGba6
-
-
Mashup Score: 2Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis - 29 day(s) ago
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Implementing nadofaragene firadenovec treatment in #NMIBC. @MarkTysonMD, Aimee Boden, & Meghann Davis @MayoClinic join @zklaassen_md @GACancerCenter to discuss implementation and logistics and the importance of a comprehensive and collaborative approach > https://t.co/uAvI7jvZrZ https://t.co/XIVCIgK9YE
-
-
Mashup Score: 22Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian - 1 month(s) ago
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Implementing nadofaragene firadenovec treatment in #NMIBC. @MarkTysonMD, Aimee Boden, & Meghann Davis @MayoClinic join @zklaassen_md @GACancerCenter to discuss implementation and logistics and the importance of a comprehensive and collaborative approach > https://t.co/uAvI7jvZrZ https://t.co/XIVCIgK9YE